In a groundbreaking study published in Nature, researchers have unveiled pivotal insights into the genomic mechanisms driving resistance to CDK4/6 inhibitors in breast cancer, emphasizing the dual roles of homologous recombination deficiency (HRD) and RB1 hemizygosity. This discovery not only elucidates the intricate relationship between BRCA2 and RB1 gene alterations but also offers promising avenues for precision oncology and therapeutic interventions.
At the heart of this investigation lies the genomic architecture of BRCA2-driven tumors. BRCA2 and RB1 are located proximally on chromosome 13q, making them susceptibility candidates for concurrent genetic events. Prior research has suggested that biallelic inactivation of BRCA2 often coincides with the deletion of broad chromosomal regions encompassing both the wild-type BRCA2 and RB1 alleles. This phenomenon implies that alterations in RB1 may be a collateral event during BRCA2 loss, potentially playing an underrecognized role in tumor biology and therapy resistance.
Leveraging a cohort analysis combining data from multiple institutions, the researchers identified a significant co-occurrence of BRCA2 and RB1 loss of heterozygosity (LOH) in germline BRCA2 (gBRCA2)-mutant breast tumors compared to tumors with wild-type BRCA2. This co-LOH pattern was independently validated in an external cohort of 46 gBRCA2-associated primary breast cancers, where over 80% exhibited concurrent BRCA2 and RB1 LOH. Notably, RB1 LOH was also apparent in approximately 35% of BRCA2 wild-type tumors, underscoring its broader oncologic significance beyond hereditary BRCA2 mutations.
These observations catalyzed the hypothesis that RB1 LOH serves as a major predisposing factor conferring resistance to CDK4/6 inhibitors, a class of targeted therapeutics revolutionizing hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer treatment. To investigate this, the team analyzed progression-free survival (PFS) and overall survival (OS) in a large cohort of 547 patients treated with first-line CDK4/6 inhibitors plus endocrine therapy (ET). The presence of RB1 LOH before treatment correlated strongly with shortened PFS and OS, indicating its predictive value for therapeutic response.
Further reinforcing these findings, analyses of pre-treatment circulating tumor DNA (ctDNA) from the PALOMA-3 clinical trial—an instrumental phase III study comparing palbociclib plus fulvestrant to fulvestrant alone—revealed that patients harboring RB1 LOH had significantly decreased PFS and OS. These effects were even more pronounced in the palbociclib combination arm, highlighting the direct interplay between RB1 genomic status and CDK4/6 inhibitor efficacy.
A particularly insightful component of the study delved into allelic configurations of RB1, focusing on the concept of hemizygosity, where only a single functional copy of RB1 remains due to heterozygous deletion. This hemizygous state was distinguished from other LOH configurations that leave multiple remaining alleles. Tumors with RB1 hemizygosity were more susceptible to acquiring a second hit in RB1—often a loss-of-function mutation—upon exposure to CDK4/6 inhibitors, facilitating complete biallelic inactivation and subsequent therapeutic resistance.
Comparative analyses confirmed that this phenomenon was specific to RB1 hemizygosity and was not mirrored by other allelic patterns. The evolutionary barrier to resistance was consequently lowered in RB1-hemizygous tumors, which require only a single additional genetic event to neutralize RB1 function, underscoring the importance of precise genomic context in resistance development.
To broaden the clinical relevance, the research delineated acquired RB1 loss-of-function (LoF) variants among patients treated with a spectrum of therapies. Significantly, only exposure to CDK4/6 inhibitors was linked to an enrichment of acquired RB1 LoF mutations, positioning RB1 inactivation as a mechanism uniquely fueled by this therapeutic pressure rather than a general consequence of cancer progression or treatment.
Addressing prognostic versus predictive dimensions, the study stratified outcomes according to RB1 allelic states, adjusting for known confounding factors such as chromosomal instability markers. While several LOH configurations portended poor overall survival, RB1 hemizygosity emerged as the single allelic state consistently associated with diminished PFS on CDK4/6 inhibitors, reinforcing its role as a predictive biomarker for therapeutic responsiveness rather than a broader prognostic factor.
These findings collectively illuminate a critical genetic determinant of CDK4/6 inhibitor failure in breast cancer, with RB1 hemizygosity predisposing tumors to evolutionarily facile resistance via biallelic inactivation. Despite the relative rarity of acquired RB1 LoF variants in the wider patient population, their prevalence and predictability in RB1-hemizygous tumors herald important clinical implications.
The study opens new horizons for patient stratification, enabling clinicians to anticipate resistance pathways and tailor surveillance strategies accordingly. Moreover, it invigorates the pursuit of targeted agents designed to exploit vulnerabilities in RB1-deficient tumors, paving the way for novel combination therapies or next-generation treatments that can circumvent or overcome resistance mechanisms.
Beyond the immediate clinical applications, the research underscores the broader paradigm wherein pre-treatment genomic landscapes forecast not only patient outcomes but also the specific molecular trajectories through which tumors adapt and evade therapies. This nuanced understanding of cancer evolution under therapeutic pressure advances the field toward increasingly personalized and dynamic oncologic care.
In sum, the elucidation of the interplay between homologous recombination deficiency, RB1 hemizygosity, and CDK4/6 inhibitor resistance represents a landmark achievement in breast cancer research. By bridging genetic insights with clinical outcomes, this work charts a promising path forward for precision medicine, poised to enhance the durability and efficacy of targeted treatments against one of the most formidable challenges in oncology.
Subject of Research:
Mechanisms of CDK4/6 inhibitor resistance in breast cancer mediated by homologous recombination deficiency and RB1 hemizygosity.
Article Title:
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.
Article References:
Safonov, A., Lee, M., Brown, D.N. et al. Homologous recombination deficiency and hemizygosity drive resistance in breast cancer. Nature (2026). https://doi.org/10.1038/s41586-026-10197-0
DOI:
https://doi.org/10.1038/s41586-026-10197-0
Tags: BRCA2 and RB1 co-deletionBRCA2 gene alterationsbreast cancer resistance mechanismsCDK4/6 inhibitor resistancechromosomal 13q alterations in cancergenomic architecture of breast tumorsgermline BRCA2 mutationshomologous recombination deficiency in cancerloss of heterozygosity in breast cancerprecision oncology in breast cancerRB1 hemizygosity in tumorstherapeutic resistance in BRCA2-mutant tumors
